TB vaccine development: where are we and why is it so difficult?

The development of an effective TB vaccine remains paramount to achieving the goal of global eradication of TB by 2050. The only licensed vaccine, BCG, has variable efficacy and is poorly effective in high burden countries. The development of promising candidate vaccines to either ‘boost’ a BCG prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkie, Morven E M, McShane, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Chest Clinic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345977/
https://www.ncbi.nlm.nih.gov/pubmed/25432943
http://dx.doi.org/10.1136/thoraxjnl-2014-205202
Descripción
Sumario:The development of an effective TB vaccine remains paramount to achieving the goal of global eradication of TB by 2050. The only licensed vaccine, BCG, has variable efficacy and is poorly effective in high burden countries. The development of promising candidate vaccines to either ‘boost’ a BCG primed immune system or replace BCG altogether is a key area for innovative research. Here, we discuss some of the issues encountered in the development of potential candidate vaccines and the future challenges.

Ejemplares similares